Cigna’s Evernorth Makes $100 Million AI Specialty Pharmacy Investment

Cigna’s Evernorth health services arm is betting $100 million that artificial intelligence can fix what patients hate most about specialty pharmacy: the labyrinth of paperwork, delayed approvals, and opaque pricing. The investment, announced July 1, 2026, backs a new AI-powered program designed to streamline how patients access and manage high-cost specialty medications for conditions like cancer, rheumatoid arthritis, and multiple sclerosis. Evernorth, which includes pharmacy benefit manager Express Scripts, aims to use machine learning to automate prior authorizations, predict patient adherence, and personalize care coordination — a move that could reshape a $300 billion market that has long frustrated both patients and employers.

Specialty drugs now account for more than half of total U.S. pharmacy spending, according to IQVIA, and their complexity demands a level of monitoring and logistics that traditional retail pharmacy cannot handle. Patients often face weeks of back-and-forth between doctors, insurers, and pharmacists to get approval for drugs that can cost $10,000 or more per month. Evernorth’s AI platform promises to cut that cycle by leveraging data across medical claims, pharmacy claims, and electronic health records to flag problems before they cause delays.

The $100 million investment is not just a check — it covers technology development, pilot programs with select health plans and employers, and a dedicated team of data scientists and pharmacists. The company says early results from internal tests show a 30% reduction in time-to-therapy for certain autoimmune drugs and a 20% improvement in medication adherence among patients using the AI-powered reminders and support tools. Evernorth’s president, Eric Palmer, stated that the goal is “to make the specialty pharmacy experience feel as simple as ordering a ride.”

Rivals are listening. CVS Health’s Caremark and UnitedHealth’s OptumRx have both launched AI initiatives, but Evernorth’s investment is among the largest dedicated solely to specialty pharmacy technology. The move also comes as Amazon Pharmacy expands into specialty drugs and as employers increasingly demand transparency and cost control from their pharmacy benefit managers. Industry analysts at Gartner note that AI in pharmacy has moved beyond pilot phases into real-world deployment, with error rates falling below 1% for well-trained models.

The broader implication is a shift in the power dynamic between PBMs and drug manufacturers. If AI can reliably predict which patients will benefit from a drug, PBMs can negotiate more aggressive discounts and enforce stricter adherence requirements. That could lower overall healthcare costs, but it also raises questions about data privacy and algorithmic bias, especially if AI decisions inadvertently disadvantage sicker or less tech-savvy patients. Patient advocacy groups have already called for transparency around the algorithms used in prior authorization decisions.

Looking ahead, Evernorth plans to expand the AI program to all its specialty pharmacy clients by the end of 2026. The company will also publish regular reports on outcomes, including time-to-therapy, patient satisfaction scores, and cost savings. If successful, this investment could accelerate the adoption of AI across the entire pharmacy supply chain — from drug discovery to dispensing. For now, the $100 million bet signals that health giants see AI not as a speculative experiment but as a core operational necessity.